Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Altamira Therapeutics Files Provisional Patent Application For OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Author: Benzinga Newsdesk | January 24, 2024 09:49am

Altamira's polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines
Fresh experimental data expected to strengthen Altamira's intellectual property around its AM-401 nanoparticles for the treatment of KRAS-driven cancers

Posted In: CYTO